{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:08:18Z","timestamp":1793286498071,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-026-00874-5","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:06:27Z","timestamp":1779296787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A scoping review of factors affecting activated clotting time measurement results"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuki","family":"Itagaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineji","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Yashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"5","key":"874_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1001\/jama.1966.03100180108036","volume":"196","author":"PG Hattersley","year":"1966","unstructured":"Hattersley PG. Activated coagulation time of whole blood. JAMA. 1966;196(5):436\u201340.","journal-title":"JAMA"},{"issue":"3","key":"874_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/MAT.0000000000001652","volume":"68","author":"ABV McMichael","year":"2022","unstructured":"McMichael ABV, Ryerson LM, Ratano D, Fan E, Faraoni D, Annich GM. 2021 ELSO Adult and Pediatric Anticoagulation Guidelines. Asaio j. 2022;68(3):303\u201310.","journal-title":"Asaio j"},{"issue":"4","key":"874_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s11239-022-02672-y","volume":"54","author":"H Dalton","year":"2022","unstructured":"Dalton H, Martin M, Garcia-Filion P, Shavelle D, Huang PH, Clark J, Beinart S, Israel A, Korpi-Steiner N. Activated clotting time in inpatient diagnostic and interventional settings. J Thromb Thrombolysis. 2022;54(4):660\u20138.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"874_CR4","first-page":"E30","volume":"63","author":"Y Miyatake","year":"2017","unstructured":"Miyatake Y, Makino S, Kubota K, Egi M, Mizobuchi S. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study. Kobe J Med Sci. 2017;63(1):E30\u20136.","journal-title":"Kobe J Med Sci"},{"issue":"3","key":"874_CR5","first-page":"351","volume":"89","author":"S Mottillo","year":"2017","unstructured":"Mottillo S, Filion KB, Joseph L, Eisenberg MJ. Defining optimal activated clotting time for percutaneous coronary intervention: A systematic review and Bayesian meta-regression. Catheter Cardiovasc Interv. 2017;89(3):351\u201366.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"874_CR6","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jtha.2024.01.001","volume":"22","author":"JH Levy","year":"2024","unstructured":"Levy JH, Sniecinski RM, Maier CL, Despotis GJ, Ghadimi K, Helms J, Ranucci M, Steiner ME, Tanaka KA, Connors JM. Finding a common definition of heparin resistance in adult cardiac surgery: communication from the ISTH SSC subcommittee on perioperative and critical care thrombosis and hemostasis. J Thromb Haemost. 2024;22(4):1249\u201357.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"874_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1051\/ject\/201850005","volume":"50","author":"L Shore-Lesserson","year":"2018","unstructured":"Shore-Lesserson L, Baker RA, Ferraris V, Greilich PE, Fitzgerald D, Roman P, Hammon J. STS\/SCA\/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass. J Extra Corpor Technol. 2018;50(1):5\u201318.","journal-title":"J Extra Corpor Technol"},{"key":"874_CR8","doi-asserted-by":"crossref","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025.","DOI":"10.1161\/CIR.0000000000001346"},{"issue":"7","key":"874_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"issue":"1","key":"874_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"issue":"4","key":"874_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1053\/j.jvca.2012.03.011","volume":"26","author":"YP Bosch","year":"2012","unstructured":"Bosch YP, Weerwind PW, Nelemans PJ, Maessen JG, Mochtar B. An evaluation of factors affecting activated coagulation time. J Cardiothorac Vasc Anesth. 2012;26(4):563\u20138.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"7","key":"874_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1046\/j.1525-1594.2000.06552.x","volume":"24","author":"L Girardi","year":"2000","unstructured":"Girardi L, Sudi K, Muntean W. Effect of heparin, platelets, activated platelets, platelet fragments, and hematocrit on activated clotting time. Artif Organs. 2000;24(7):507\u201313.","journal-title":"Artif Organs"},{"issue":"6","key":"874_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/bja\/85.6.896","volume":"85","author":"A Vuylsteke","year":"2000","unstructured":"Vuylsteke A, Mills RJ, Crosbie AE, Burns TI, Latimer RD. Increased pre-operative platelet counts are a possible predictor for reduced sensitivity to heparin. Br J Anaesth. 2000;85(6):896\u20138.","journal-title":"Br J Anaesth"},{"issue":"6","key":"874_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1177\/0267659117692661","volume":"32","author":"J Ichikawa","year":"2017","unstructured":"Ichikawa J, Mori T, Kodaka M, Nishiyama K, Ozaki M, Komori M. Changes in heparin dose response slope during cardiac surgery: possible result in inaccuracy in predicting heparin bolus dose requirement to achieve target ACT. Perfusion. 2017;32(6):474\u201380.","journal-title":"Perfusion"},{"issue":"4","key":"874_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/ajcp\/91.4.430","volume":"91","author":"AP Bode","year":"1989","unstructured":"Bode AP, Eick L. Lysed platelets shorten the activated coagulation time (ACT) of heparinized blood. Am J Clin Pathol. 1989;91(4):430\u20134.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"874_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1055\/s-0038-1646392","volume":"66","author":"AP Bode","year":"1991","unstructured":"Bode AP, Castellani WJ, Hodges ED, Yelverton S. The effect of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT). Thromb Haemost. 1991;66(2):213\u20137.","journal-title":"Thromb Haemost"},{"issue":"5","key":"874_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0049-3848(94)90025-6","volume":"73","author":"AP Bode","year":"1994","unstructured":"Bode AP, Lust RM. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity. Thromb Res. 1994;73(5):285\u2013300.","journal-title":"Thromb Res"},{"issue":"3","key":"874_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1540-8191.2007.00535.x","volume":"23","author":"AR Srivastava","year":"2008","unstructured":"Srivastava AR, Banerjee A, Misra BB, Minhas H, Virmani S. Does hemodilution by the crystalloid priming solution derange the efficacy of anticoagulation during cardiopulmonary bypass? J Card Surg. 2008;23(3):239\u201345.","journal-title":"J Card Surg"},{"issue":"1","key":"874_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00001721-200401000-00009","volume":"15","author":"VG N","year":"2004","unstructured":"VG N. Hemodilution with lactated Ringer\u2019s solution causes hypocoagulability in rabbits. Blood coagulation fibrinolysis: Int J haemostasis Thromb. 2004;15(1):55\u20139.","journal-title":"Blood coagulation fibrinolysis: Int J haemostasis Thromb"},{"issue":"2","key":"874_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1051\/ject\/2001332100","volume":"33","author":"SA Kmiecik","year":"2001","unstructured":"Kmiecik SA, Liu J-L, Vaadia TS, Nichols JD, Kohtz RJ, Mills NJ, Petterson CM, Stammers AH. Quantitative Evaluation of Hypothermia, Hyperthermia, and Hemodilution on Coagulation. J Extracorpor Technol. 2001;33(2):100\u20135.","journal-title":"J Extracorpor Technol"},{"issue":"4","key":"874_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.surg.2012.07.011","volume":"152","author":"A JA","year":"2012","unstructured":"JA A. The storage lesion of packed red blood cells affects coagulation. Surgery. 2012;152(4):697\u2013702. discussion 702\u2009\u2013\u2009693.","journal-title":"Surgery"},{"key":"874_CR22","doi-asserted-by":"crossref","unstructured":"Fish KJ, Sarnquist FH, van Steennis C, Mitchell RS, Hilberman M, Jamieson SW, Linet OI, Miller DC. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovasc Surg. 1986;91(3):436\u201342..","DOI":"10.1016\/S0022-5223(19)36060-X"},{"issue":"4","key":"874_CR23","first-page":"394","volume":"63","author":"M MT","year":"1984","unstructured":"MT M, JC W, BS B. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg. 1984;63(4):394\u20138.","journal-title":"Anesth Analg"},{"key":"874_CR24","doi-asserted-by":"crossref","unstructured":"RF. B: Platelets and whole blood coagulation. Perfusion. 2000;15(1):41\u201350.","DOI":"10.1177\/026765910001500107"},{"issue":"8","key":"874_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0002-9149(99)80616-X","volume":"15","author":"DJCR Moliterno","year":"1995","unstructured":"Moliterno DJCR, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb\/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol. Mar 1995;15(8):559\u201362.","journal-title":"Am J Cardiol"},{"issue":"5","key":"874_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00059-003-2349-3","volume":"28","author":"R Zahn","year":"2003","unstructured":"Zahn R, Haubelt H, Bechtloff S, Schneider S, Frilling B, Rustige J, Marsalek P, Seidl K, Senges J, Hellstern P. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb\/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Herz. 2003;28(5):445\u201352.","journal-title":"Herz"},{"issue":"3","key":"874_CR27","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1053\/j.jvca.2016.12.001","volume":"31","author":"M Lopez","year":"2017","unstructured":"Lopez M, Feng C, Vasilyeva O, Eaton MP. Supplemental Antithrombin Is Effective in Achieving Adequate Anticoagulation in Infants and Children With an Inadequate Response to Heparin. J Cardiothorac Vasc Anesth. 2017;31(3):896\u2013900.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"874_CR28","doi-asserted-by":"crossref","unstructured":"Lemmer JH Jr., Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2002;123(2):213\u20137.","DOI":"10.1067\/mtc.2002.119060"},{"issue":"5","key":"874_CR29","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/00000539-200005000-00013","volume":"90","author":"L JH","year":"2000","unstructured":"JH L, F M, CD FS. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg. 2000;90(5):1076\u20139.","journal-title":"Anesth Analg"},{"key":"874_CR30","doi-asserted-by":"crossref","unstructured":"Garvin S, Fitzgerald D, Muehlschlegel JD, Perry TE, Fox AA, Shernan SK, Collard CD, Aranki S, Body SC. Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg. 2010;111(4):856\u201361..","DOI":"10.1213\/ANE.0b013e3181ce1ffa"},{"issue":"3","key":"874_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0735-1097(02)02762-6","volume":"41","author":"JD Marmur","year":"2003","unstructured":"Marmur JD, Anand SX, Bagga RS, Fareed J, Pan CM, Sharma SK, Richard MF. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol. 2003;41(3):394\u2013402.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"874_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/107602960501100202","volume":"11","author":"JMGJ Wilson","year":"2005","unstructured":"Wilson JMGJ, Harlan M, Bracey A, Allison P, Schooley C, Pinto K. High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. Clin Appl Thromb Hemost. Apr; 2005;11(2):127\u201338.","journal-title":"Clin Appl Thromb Hemost"},{"key":"874_CR33","unstructured":"WANG J-qS Xu-bo YANG Jin-gang, HU Da-yi. In vitroanticoagulation monitoring of low-molecular-weight heparin. Chin Med J. 2009;122(10):1199\u2013202."},{"issue":"11","key":"874_CR34","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/PCC.0000000000002527","volume":"21","author":"LM Ryerson","year":"2020","unstructured":"Ryerson LM, Balutis KR, Granoski DA, Nelson LR, Massicotte MP, Lequier LL, Bauman ME. Prospective Exploratory Experience With Bivalirudin Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation. Pediatr Crit Care Med. 2020;21(11):975\u201385.","journal-title":"Pediatr Crit Care Med"},{"issue":"4","key":"874_CR35","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1213\/01.ane.0000278868.23814.3b","volume":"105","author":"KA Tanaka","year":"2007","unstructured":"Tanaka KA, Szlam F, Sun HY, Taketomi T, Levy JH. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Anesth Analg. 2007;105(4):933\u20139. table of contents.","journal-title":"Anesth Analg"},{"issue":"4","key":"874_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1051\/ject\/200537364","volume":"37","author":"ML Zucker","year":"2005","unstructured":"Zucker ML, Koster A, Prats J, Laduca FM. Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery. J Extra Corpor Technol. 2005;37(4):364\u20138.","journal-title":"J Extra Corpor Technol"},{"issue":"10","key":"874_CR37","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.amjcard.2004.01.076","volume":"93","author":"JM Schussler","year":"2004","unstructured":"Schussler JM, Lander SR, Wissinger LA, Anwar A, Donsky MS, Johnson KB, Vallabhan RC, Wischmeyer JB. Validation of the i-STAT handheld activated clotting time for use with bivalirudin. Am J Cardiol. 2004;93(10):1318\u20139.","journal-title":"Am J Cardiol"},{"issue":"2","key":"874_CR38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijcard.2010.02.044","volume":"148","author":"L Rossig","year":"2011","unstructured":"Rossig L, Genth-Zotz S, Rau M, Heyndrickx GR, Schneider T, Gulba DC, Desaga M, Buerke M, Harder S, Zeiher AM, et al. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study. Int J Cardiol. 2011;148(2):214\u20139.","journal-title":"Int J Cardiol"},{"issue":"12","key":"874_CR39","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/oxfordjournals.eurheartj.a014800","volume":"17","author":"UMM Zeymer","year":"1996","unstructured":"Zeymer UMM, Neuhaus KL. Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction. Eur Heart J. Dec; 1996;17(12):1836\u201340.","journal-title":"Eur Heart J"},{"issue":"2","key":"874_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.thromres.2004.02.012","volume":"113","author":"IPKD Casserly","year":"2004","unstructured":"Casserly IPKD, Gray WA, Gibson PH, Lauer MA, Reginelli JP, Moliterno DJ. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thromb Res. 2004;113(2):115\u201321.","journal-title":"Thromb Res"},{"issue":"3","key":"874_CR41","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1213\/01.ane.0000226098.95698.0f","volume":"103","author":"A Koster","year":"2006","unstructured":"Koster A, Spiess B, Jurmann M, Dyke CM, Smedira NG, Aronson S, Lincoff MA. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the EVOLUTION OFF trial. Anesth Analg. 2006;103(3):540\u20134.","journal-title":"Anesth Analg"},{"issue":"6","key":"874_CR42","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/0091270010372627","volume":"51","author":"K Akimoto","year":"2011","unstructured":"Akimoto K, Klinkhardt U, Zeiher A, Niethammer M, Harder S. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters. J Clin Pharmacol. 2011;51(6):805\u201318.","journal-title":"J Clin Pharmacol"},{"key":"874_CR43","doi-asserted-by":"crossref","unstructured":"Iwama H, Watanabe K, Obara S. In vitro relationship between the blood nafamostat concentration and activated coagulation time. Can J Anaesth. 2003;50(6):621\u20132..","DOI":"10.1007\/BF03018658"},{"issue":"4","key":"874_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1525-1594.2005.29061.x","volume":"29","author":"H Nakae","year":"2005","unstructured":"Nakae H, Tajimi K. Correlation between serum nafamostat mesilate and activated coagulation time during continuous hemodiafiltration. Artif Organs. 2005;29(4):352\u20134.","journal-title":"Artif Organs"},{"key":"874_CR45","doi-asserted-by":"crossref","unstructured":"Kresowik TF, Wakefield TW, Fessler RD 2nd, Stanley JC. Anticoagulant effects of protamine sulfate in a canine model. J Surg Res. 1988;45(1):8\u201314.","DOI":"10.1016\/0022-4804(88)90014-5"},{"issue":"4","key":"874_CR46","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1213\/00000539-199810000-00008","volume":"87","author":"T Mochizuki","year":"1998","unstructured":"Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87(4):781\u20135.","journal-title":"Anesth Analg"},{"issue":"5 Suppl 1","key":"874_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/0888-6296(89)90823-5","volume":"3","author":"DBB Royston","year":"1989","unstructured":"Royston DBB, Taylor KM, Sapsford RM. Reduced blood loss following open heart surgery with aprotinin (Trasylol) is associated with an increase in intraoperative activated clotting time (ACT). J Cardiothorac Anesth. Oct; 1989;3(5 Suppl 1):80.","journal-title":"J Cardiothorac Anesth"},{"issue":"6","key":"874_CR48","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1097\/00000542-199212000-00006","volume":"77","author":"JSLC Wang","year":"1992","unstructured":"Wang JSLC, Hung WT, Karp RB. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology. Dec; 1992;77(6):1080\u20134.","journal-title":"Anesthesiology"},{"issue":"5","key":"874_CR49","first-page":"II410","volume":"86","author":"H BJ","year":"1992","unstructured":"BJ H. Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation. 1992;86(5):II410\u2013412.","journal-title":"Circulation"},{"issue":"1","key":"874_CR50","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/0003-4975(94)00798-C","volume":"59","author":"GJJJ Despotis","year":"1995","unstructured":"Despotis GJJJ, Joiner-Maier D, Alsoufiev AL, Triantafillou AN, Goodnough LT, Santoro SA, Lappas DG. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements. Ann Thorac Surg. Jan; 1995;59(1):106\u201311.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"874_CR51","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1213\/00000539-199608000-00043","volume":"83","author":"YJHR Gu","year":"1996","unstructured":"Gu YJHR, van Oeveren W. Extrinsic pathway\u2013associated activated clotting time for anticoagulation monitoring during cardiopulmonary bypass. Anesth Analg. Aug; 1996;83(2):433.","journal-title":"Anesth Analg"},{"issue":"3","key":"874_CR52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1051\/ject\/200537265","volume":"37","author":"DDP Machin","year":"2005","unstructured":"Machin DDP. The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement. J Extra Corpor Technol. Sep; 2005;37(3):265\u201371.","journal-title":"J Extra Corpor Technol"},{"issue":"1","key":"874_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1051\/ject\/200436151","volume":"36","author":"K Jones","year":"2004","unstructured":"Jones K, Nasrallah F, Darling E, Clay N, Searles B. The In Vitro Effects of Aprotinin on Twelve Different ACT Tests. J Extracorpor Technol. 2004;36(1):51\u20137.","journal-title":"J Extracorpor Technol"},{"issue":"4","key":"874_CR54","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S0022-5223(19)34702-6","volume":"104","author":"JS Wang","year":"1992","unstructured":"Wang JS, Lin CY, Hung WT, Thisted RA, Karp RB. In vitro effects of aprotinin on activated clotting time measured with different activators. J Thorac Cardiovasc Surg. 1992;104(4):1135\u201340.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"874_CR55","doi-asserted-by":"publisher","first-page":"110020","DOI":"10.1016\/j.jclinane.2020.110020","volume":"67","author":"YT Yao","year":"2020","unstructured":"Yao YT, He LX, Tan JC. The effect of tranexamic acid on the values of activated clotting time in patients undergoing cardiac surgery: A PRISMA-compliant systematic review and meta-analysis. J Clin Anesth. 2020;67:110020.","journal-title":"J Clin Anesth"},{"issue":"3","key":"874_CR56","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0002-8703(98)70223-6","volume":"136","author":"RJ Chang","year":"1998","unstructured":"Chang RJ, Doherty TM, Goldberg SL. How does warfarin affect the activated coagulation time? Am Heart J. 1998;136(3):477\u20139.","journal-title":"Am Heart J"},{"issue":"6","key":"874_CR57","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jce.13483","volume":"29","author":"H Yamaji","year":"2018","unstructured":"Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Hirohata S, Kusachi S. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. J Cardiovasc Electrophysiol. 2018;29(6):835\u201343.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"874_CR58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10840-020-00863-2","volume":"62","author":"M Wieczorek","year":"2021","unstructured":"Wieczorek M, Bogossian H, Bandorski D, Hoeltgen R. Uninterrupted use of direct oral anticoagulants versus vitamin K antagonists for catheter ablation of atrial fibrillation with PVAC gold: incidence of silent cerebral microembolic events. J Interv Card Electrophysiol. 2021;62(1):39\u201347.","journal-title":"J Interv Card Electrophysiol"},{"issue":"1","key":"874_CR59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.jvca.2023.11.015","volume":"38","author":"KG Ural","year":"2024","unstructured":"Ural KG, Moridzadeh SS, Busch EH, Masri OE, Burton JH, Morin DP. Use of a New Standardized Unfractionated Heparin Protocol for Left-Sided Ablation Procedures Improves Time in the Therapeutic ACT Range. J Cardiothorac Vasc Anesth. 2024;38(1):67\u201372.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"1","key":"874_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s42466-021-00105-4","volume":"3","author":"F Hartig","year":"2021","unstructured":"Hartig F, Birschmann I, Peter A, Horber S, Ebner M, Sonnleitner M, Spencer C, Bombach P, Stefanou MI, Tunnerhoff J, et al. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban. Neurol Res Pract. 2021;3(1):9.","journal-title":"Neurol Res Pract"},{"key":"874_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2023.07.092","volume":"204","author":"E Shibahashi","year":"2023","unstructured":"Shibahashi E, Abe T, Kamishima K, Ebihara S, Moriyama T, Shimazaki K, Saito K, Uchigata Y, Jujo K. Direct Oral Anticoagulants Affect Activated Clotting Time During and Bleeding Events After Percutaneous Coronary Intervention. Am J Cardiol. 2023;204:1\u20138.","journal-title":"Am J Cardiol"},{"issue":"3","key":"874_CR62","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10840-019-00650-8","volume":"59","author":"H Songqun","year":"2020","unstructured":"Songqun H, Chunling W, Zhifu G, Xinmiao H, Jiang C. Effects of rivaroxaban on activated clotting time in catheter ablation for atrial fibrillation in Chinese patients. J Interv Card Electrophysiol. 2020;59(3):509\u201316.","journal-title":"J Interv Card Electrophysiol"},{"issue":"12","key":"874_CR63","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1111\/jce.14260","volume":"30","author":"H Yamaji","year":"2019","unstructured":"Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Hirohata S, Kusachi S. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. J Cardiovasc Electrophysiol. 2019;30(12):2823\u201333.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"10","key":"874_CR64","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40261-016-0435-6","volume":"36","author":"H Yamaji","year":"2016","unstructured":"Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Komtasubara I, Kusachi S. Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants. Clin Drug Investig. 2016;36(10):837\u201348.","journal-title":"Clin Drug Investig"},{"key":"874_CR65","doi-asserted-by":"publisher","first-page":"106994","DOI":"10.1016\/j.vph.2022.106994","volume":"144","author":"F Negro","year":"2022","unstructured":"Negro F, Caravelli P, Morganti R, Casini M, Ruocco L, Tripodi A, De Caterina R. The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time. Vascul Pharmacol. 2022;144:106994.","journal-title":"Vascul Pharmacol"},{"issue":"1","key":"874_CR66","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13054-017-1619-z","volume":"21","author":"M Ebner","year":"2017","unstructured":"Ebner M, Birschmann I, Peter A, Spencer C, Hartig F, Kuhn J, Blumenstock G, Zuern CS, Ziemann U, Poli S. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care. 2017;21(1):32.","journal-title":"Crit Care"},{"key":"874_CR67","doi-asserted-by":"crossref","unstructured":"Benali KVJ, Hammache N, Guenancia C, Hooks D, Magnin-Poull I, Toussaint-Hacquard M, de Chillou C, Sellal JM. Running after activated clotting time values in patients receiving direct oral anticoagulants: a potentially dangerous race. results from a prospective study in atrial fibrillation catheter ablation procedures. J Clin Med. 2021;10(18):4240.","DOI":"10.3390\/jcm10184240"},{"issue":"3","key":"874_CR68","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10840-017-0274-2","volume":"49","author":"LC Brendel","year":"2017","unstructured":"Brendel LC, Dobler F, Hessling G, Michel J, Braun SL, Steinsiek AL, Groha P, Eckl R, Deisenhofer I, Hyseni A, et al. The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban. J Interv Card Electrophysiol. 2017;49(3):237\u201344.","journal-title":"J Interv Card Electrophysiol"},{"key":"874_CR69","doi-asserted-by":"publisher","first-page":"107602961989512","DOI":"10.1177\/1076029619895120","volume":"26","author":"F Siddiqui","year":"2020","unstructured":"Siddiqui F, Tafur A, Bontekoe E, Iqbal O, Jeske W, Mehrotra S, Hoppensteadt D, Ramacciotti E, Fareed J. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa. Clin Appl Thromb Hemost. 2020;26:1076029619895120.","journal-title":"Clin Appl Thromb Hemost"},{"key":"874_CR70","doi-asserted-by":"crossref","unstructured":"Capdevila LFC, Desvages M, Harroche A, Bally C, Abbes A, d\u2019Oiron R, Frenzel L, Borgel D, Lasne D. Emicizumab does not interfere with the activated clotting time. Haemophilia. 2022;28(2):362\u20136.","DOI":"10.1111\/hae.14497"},{"issue":"1","key":"874_CR71","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/hae.14452","volume":"28","author":"KA Tanaka","year":"2022","unstructured":"Tanaka KA, Henderson R, Thangaraju K, Morita Y, Mazzeffi MA, Strauss E, Katneni U, Buehler PW. In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients. Haemophilia. 2022;28(1):183\u201390.","journal-title":"Haemophilia"},{"issue":"11","key":"874_CR72","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1053\/j.jvca.2020.06.027","volume":"34","author":"FMS Falter","year":"2020","unstructured":"Falter FMS, Matthews C, Kemna E, Ca\u00f1ameres J, Besser M. Evaluation of Point-of-Care ACT Coagulometers and Anti-Xa Activity During Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth. Nov; 2020;34(11):2921\u20137.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"1","key":"874_CR73","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12871-019-0846-z","volume":"619","author":"DNE Dirkmann","year":"2019","unstructured":"Dirkmann DNE, Britten MW, Peters J. Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability. BMC Anesthesiol. Sep 2019;619(1):174.","journal-title":"BMC Anesthesiol"},{"issue":"3","key":"874_CR74","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1373\/jalm.2019.029066","volume":"4","author":"EWMSM Kemna","year":"2019","unstructured":"Kemna EWMSM, Vlachojannis GJ, Falter F, Milan\u00e9-Santman A, Hesselink T, Scholten M, Krabbe JG. A Multicenter Comparison of 2 Point-of-Care Activated Clotting Time Test Systems. J Appl Lab Med. Nov; 2019;4(3):468\u201370.","journal-title":"J Appl Lab Med"},{"issue":"4","key":"874_CR75","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/labmed\/lmz014","volume":"50","author":"TZ Thompson","year":"2019","unstructured":"Thompson TZ, Kunak RL, Savage NM, Agarwal S, Chazelle J, Singh G. Intraoperative Monitoring of Heparin: Comparison of Activated Coagulation Time and Whole Blood Heparin Measurements by Different Point-of-Care Devices with Heparin Concentration by Laboratory-Performed Plasma Anti-Xa Assay. Lab Med. 2019;50(4):348\u201356.","journal-title":"Lab Med"},{"key":"874_CR76","doi-asserted-by":"crossref","unstructured":"Kemna EWKC, Oude Luttikhuis-Spanjer AM, Majoor S, Boudrie R, Speekenbrink RG, Hoffman R, Krabbe JG. A two site comparison of two point-of-care activated clotting time systems. Clin Chem Lab Med. 2017;55(1):e13\u2013e16.","DOI":"10.1515\/cclm-2016-0317"},{"issue":"1","key":"874_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1051\/ject\/201244015","volume":"44","author":"JWHR Ojito","year":"2012","unstructured":"Ojito JWHR, Burgos MM, Lim H, Huynh M, Velis E, Arocha M, Tirotta CF, Burke RP. Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution. J Extra Corpor Technol. Mar; 2012;44(1):15\u201320.","journal-title":"J Extra Corpor Technol"},{"key":"874_CR78","doi-asserted-by":"crossref","unstructured":"Li HSC, Rao V, Yip PM. A comparative analysis of four activated clotting time measurement devices in cardiac surgery with cardiopulmonary bypass. Perfusion. 2021;36(6):610\u20139.","DOI":"10.1177\/0267659120949351"},{"issue":"4","key":"874_CR79","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1053\/j.jvca.2018.01.027","volume":"32","author":"A Maslow","year":"2018","unstructured":"Maslow A, Chambers A, Cheves T, Sweeney J. Assessment of Heparin Anticoagulation Measured Using i-STAT and Hemochron Activated Clotting Time. J Cardiothorac Vasc Anesth. 2018;32(4):1603\u20138.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"874_CR80","doi-asserted-by":"crossref","unstructured":"Sol\u00eds Clavijo DCA, Pe\u00f1a NA, Caballero G\u00e1lvez S, Arellano N\u00fa\u00f1ez F, Carballo Caro JM, Mu\u00f1oz-Cacho P, Toc\u00f3n Al\u00e9 C. Variability of three activated clotting time point-of-care systems in cardiac surgery: reinforcing available evidence. Perfusion. 2022;37(7):711\u20134.","DOI":"10.1177\/02676591211023687"},{"issue":"1","key":"874_CR81","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1051\/ject\/202153057","volume":"53","author":"NPATA Vranken","year":"2021","unstructured":"Vranken NPATA, Orbons T, Barenbrug PJC, Weerwind PW. Point-of-Care Measurement of Kaolin Activated Clotting Time during Cardiopulmonary Bypass: A Single Sample Comparison between ACT Plus and i-STAT. J Extra Corpor Technol. Mar; 2021;53(1):57\u201361.","journal-title":"J Extra Corpor Technol"},{"issue":"3","key":"874_CR82","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1051\/ject\/202052212","volume":"52","author":"SAM Nilsson","year":"2020","unstructured":"Nilsson SAM, Svenmarker S. Can We Rely on the Activated Clotting Time to Measure Heparin Anticoagulation A Clinical Evaluation of Two ACT Monitors. J Extra Corpor Technol. Sep; 2020;52(3):212\u20137.","journal-title":"J Extra Corpor Technol"},{"issue":"3","key":"874_CR83","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1373\/jalm.2017.024414","volume":"2","author":"NL Korpi-Steiner","year":"2017","unstructured":"Korpi-Steiner NL, Walz JM, Schanzer A, Rao LV. Comparison of Point-of-Care Activated Clotting Time Methods in Different Clinical Settings in a Large Academic Medical Center. J Appl Lab Med. 2017;2(3):356\u201366.","journal-title":"J Appl Lab Med"},{"issue":"5","key":"874_CR84","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1309\/AJCPSF8ASGONNQM6","volume":"135","author":"EL Lewandrowski","year":"2011","unstructured":"Lewandrowski EL, Van Cott EM, Gregory K, Jang IK, Lewandrowski KB. Clinical evaluation of the i-STAT kaolin activated clotting time (ACT) test in different clinical settings in a large academic urban medical center: comparison with the Medtronic ACT Plus. Am J Clin Pathol. 2011;135(5):741\u20138.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"874_CR85","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1213\/ane.0b013e31819bcc9c","volume":"108","author":"KA Tanaka","year":"2009","unstructured":"Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009;108(5):1433\u201346.","journal-title":"Anesth Analg"},{"key":"874_CR86","doi-asserted-by":"crossref","unstructured":"Benali K, Verain J, Hammache N, Guenancia C, Hooks D, Magnin-Poull I, Toussaint-Hacquard M, de Chillou C, Sellal JM. Running after activated clotting time values in patients receiving direct oral anticoagulants: a potentially dangerous race. results from a prospective study in atrial fibrillation catheter ablation procedures. J Clin Med. 2021;10(18).","DOI":"10.3390\/jcm10184240"},{"key":"874_CR87","doi-asserted-by":"publisher","first-page":"106994","DOI":"10.1016\/j.vph.2022.106994","volume":"144","author":"N F","year":"2022","unstructured":"F N, A PCRMMCLR. The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time. Vascul Pharmacol. 2022;144:106994.","journal-title":"Vascul Pharmacol"},{"issue":"1","key":"874_CR88","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13054-021-03554-0","volume":"25","author":"R Descamps","year":"2021","unstructured":"Descamps R, Moussa MD, Besnier E, Fischer MO, Preau S, Tamion F, Daubin C, Cousin N, Vincentelli A, Goutay J, et al. Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): a multicenter cohort study. Crit Care. 2021;25(1):127.","journal-title":"Crit Care"},{"key":"874_CR89","unstructured":"ECLS O. ELSO anticoagulation guideline. The Extracorporeal Life Support Organization (ELSO) Ann Arbor 2014."},{"issue":"5","key":"874_CR90","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/0267659120952982","volume":"36","author":"A Willems","year":"2021","unstructured":"Willems A, Roeleveld PP, Labarinas S, Cyrus JW, Muszynski JA, Nellis ME, Karam O. Anti-Xa versus time-guided anticoagulation strategies in extracorporeal membrane oxygenation: a systematic review and meta-analysis. Perfusion. 2021;36(5):501\u201312.","journal-title":"Perfusion"},{"issue":"1S","key":"874_CR91","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/SHK.0000000000001686","volume":"56","author":"JB Brill","year":"2021","unstructured":"Brill JB, Brenner M, Duchesne J, Roberts D, Ferrada P, Horer T, Kauvar D, Khan M, Kirkpatrick A, Ordonez C, et al. The Role of TEG and ROTEM in Damage Control Resuscitation. Shock. 2021;56(1S):52\u201361.","journal-title":"Shock"},{"key":"874_CR92","doi-asserted-by":"crossref","unstructured":"Santos AS, Oliveira AJF, Barbosa MCL, Nogueira JLD. Viscoelastic haemostatic assays in the perioperative period of surgical procedures: Systematic review and meta-analysis. J Clin Anesth. 2020;64.","DOI":"10.1016\/j.jclinane.2020.109809"},{"issue":"2","key":"874_CR93","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jss.2016.03.008","volume":"203","author":"AC Deppe","year":"2016","unstructured":"Deppe AC, Weber C, Zimmermann J, Kuhn EW, Slottosch I, Liakopoulos OJ, Choi YH, Wahlers T. Point-of-care thromboelastography\/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res. 2016;203(2):424\u201333.","journal-title":"J Surg Res"},{"issue":"4","key":"874_CR94","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.21037\/jtd.2019.04.39","volume":"11","author":"C Li","year":"2019","unstructured":"Li C, Zhao Q, Yang K, Jiang L, Yu J. Thromboelastography or rotational thromboelastometry for bleeding management in adults undergoing cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. J Thorac Dis. 2019;11(4):1170\u201381.","journal-title":"J Thorac Dis"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00874-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00874-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00874-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:03:08Z","timestamp":1784041388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00874-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00874-5","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}